
Phase II results presented by genomics-based discovery company Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

Novartis has failed to convince NICE that its revised patient access scheme for Afinitor would make the kidney cancer drug …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

